Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial

Abstract
No abstract available
Funding Information
  • National Health and Medical Research Council (GNT1135955)
  • NHMRC (GNT1132975)
  • Global Health Innovative Technology Fund (grant G2016-226)

This publication has 19 references indexed in Scilit: